Neumora Therapeutics, Inc. Common Stock
HealthcareNASDAQ:NMRA · NASDAQ Global Select
+$0.00 today
Vol 0.72M · Avg 1.22M
Cash Flow
Check whether earnings turn into cash
Use operating cash flow, capital spending, free cash flow, and financing activity to see how much value is left for reinvestment or owners.
Free Cash Flow
Net Income to FCF bridge
Analysis
Analysis will appear once cash flow data is available for this period.
Cash Flow Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Net Income | -$236.9M +2.8% | -$243.8M -3.3% | -$235.9M -80.2% | -$130.9M +44.8% | -$237.3M | $487.6M | $476.4M | $465.2M |
| Depreciation & Amortization | $208.0K | $0 -100.0% | $668.0K +12.5% | $594.0K +10.4% | $538.0K | $374.2M | $1.2B | $631.8M |
| Deferred Income Tax | $0 | $0 | $0 | $0 +100.0% | -$53.0K | $1.4B | -$1.5B | $304.2M |
| Stock-Based Compensation | $29.9M -25.3% | $40.0M +132.0% | $17.2M +107.8% | $8.3M +94.2% | $4.3M | $489.0M | $354.6M | -$1.6B |
| Change in Working Capital | -$437.0K -101.9% | $22.6M +354.4% | -$8.9M -28.1% | -$6.9M -623.0% | -$961.0K | $350.4M | -$1.6B | $1.5B |
| Accounts Receivables | $0 | $0 | $0 | $0 | $0 | $592.6M | $1.3B | $626.2M |
| Inventory | $0 | $0 | $0 | $0 | $0 | $1.0B | $1.2B | $1.1B |
| Accounts Payables | $71.0K -97.5% | $2.9M +594.5% | -$581.0K +53.4% | -$1.2M -64.2% | -$759.0K | $948.2M | -$1.5B | $433.0M |
| Other Working Capital | -$508.0K -102.6% | $19.8M +337.6% | -$8.3M -45.9% | -$5.7M -2722.8% | -$202.0K | $567.4M | $1.3B | $601.0M |
| Other Non-Cash Items | $841.0K +147.4% | -$1.8M -102.8% | $63.6M +352.5% | $14.1M -91.1% | $158.1M | $1.4B | -$1.5B | $300.0M |
| Operating Cash Flow | -$206.4M -12.8% | -$182.9M -12.0% | -$163.3M -42.1% | -$114.9M -52.3% | -$75.4M | $7.2B | $8.9B | $10.5B |
| Capital Expenditures | $0 | $0 +100.0% | -$117.0K +77.1% | -$511.0K +37.5% | -$817.0K | $664.0M | $1.4B | $697.6M |
| Acquisitions (Net) | $0 +100.0% | -$775.0K | $0 | $0 | $0 | $937.0M | $1.1B | $1.3B |
| Purchases of Investments | -$85.8M +72.5% | -$312.2M -186.3% | -$109.1M +51.8% | -$226.4M | $0 | $444.2M | $1.4B | $1.3B |
| Sales of Investments | $251.2M +3.6% | $242.4M +36.1% | $178.2M +147.9% | $71.9M | $0 | $822.2M | $318.2M | -$1.5B |
| Other Investing Activities | $3.2M | $0 +100.0% | -$4.6M +64.7% | -$13.0M | $0 | $616.4M | $370.0M | $1.2B |
| Investing Cash Flow | $168.5M +338.8% | -$70.6M -209.6% | $64.4M +138.3% | -$168.0M -20464.6% | -$817.0K | $4.8B | $6.4B | $5.1B |
| Debt Repayment | $57.2M | $0 | $0 | $0 | $0 | $680.8M | $759.2M | $1.1B |
| Common Stock Issued | $19.9M +45.5% | $13.7M -94.1% | $233.4M | $0 -100.0% | $960.0K | $778.8M | $946.8M | $812.4M |
| Common Stock Repurchased | $0 | $0 +100.0% | -$491.0K | $0 | $0 | $351.8M | -$1.6B | $1.5B |
| Dividends Paid | $0 | $0 | $0 | $0 | $0 | $535.2M | $613.6M | $692.0M |
| Other Financing Activities | $0 -100.0% | $7.9M +934.3% | -$948.0K -126.9% | $3.5M +157.8% | $1.4M | -$1.6B | $1.3B | $1.1B |
| Financing Cash Flow | $77.1M +256.8% | $21.6M -90.7% | $231.9M +100.4% | $115.7M -60.6% | $293.5M | $12.2B | $13.9B | -$15.5B |
| Effect of Forex Changes | $0 | $0 | $0 | $0 | $0 | $1.3B | $1.1B | $990.2M |
| Net Change in Cash | $39.2M +116.9% | -$231.9M -274.3% | $133.0M +179.6% | -$167.2M -176.9% | $217.3M | $3.2B | $4.9B | $6.5B |
| Free Cash Flow | -$206.4M -12.8% | -$182.9M -12.0% | -$163.4M -41.6% | -$115.4M -51.4% | -$76.2M | $8.6B | -$16.8B | $11.1B |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Alumis Inc. Common Stock
NASDAQ:ALMS
$2.98B
RAPT Therapeutics, Inc.
RAPT
$959.26M
Lexicon Pharmaceuticals, Inc.
NASDAQ:LXRX
$852.86M
Omeros Corporation
NASDAQ:OMER
$632.20M
4D Molecular Therapeutics, Inc.
NASDAQ:FDMT
$461.60M
Prothena Corporation plc
NASDAQ:PRTA
$431.91M
Autolus Therapeutics plc
NASDAQ:AUTL
$415.18M
Bicycle Therapeutics plc
NASDAQ:BCYC
$281.05M
Fulcrum Therapeutics, Inc.
NASDAQ:FULC
$186.68M
ADC Therapeutics S.A.
NYSE:ADCT
$133.55M
SEC Filings
Recent regulatory filings
No filings found.
Does NMRA generate free cash flow?
Neumora Therapeutics, Inc. Common Stock (NMRA) generated -$206,440,000.00 of free cash flow in fiscal 2025.
How much operating cash flow does NMRA produce?
Operating cash flow was -$206,440,000.00, before capital expenditures of $0.00.
Explore More
Continue the stock analysis
Jump to another research area for this company.